Under the settlement and cross-license agreement, Bavarian Nordic will grant a license to its MVA-BN patents, in return for Oxford BioMedica granting a license to its heterologous prime-boost patents and a sub-license under poxvirus patents licensed to Oxford BioMedica by Sanofi-aventis. Both firms will make undisclosed milestone and royalty payments on the future development of their respective products.
Under the settlement, all pending litigation will cease and all oppositions filed against Bavarian Nordic’s patents at the European Patent Office, will be withdrawn. In addition both companies have agreed to initiate business discussions concerning a possible future collaboration based on each company’s expertise in poxvirus vaccines, and Bavarian Nordic’s commercial manufacturing capability.
John Dawson, CEO of Oxford BioMedica, and Anders Hedegaard, CEO of Bavarian Nordic, said: “This settlement brings to an end the legal disputes between the two companies and provides a basis for both companies to progress their respective vaccine businesses.”